Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending October 28, 2011. The report details a specific share repurchase transaction executed under shareholder authority granted at the Annual General Meeting on May 5, 2011.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on capital structure changes related to share buybacks.
- Shares Purchased: 800,000 Ordinary shares of 25 pence each.
- Purchase Date: October 28, 2011.
- Price Range: Highest price paid was 1,398.5 pence per share; lowest price paid was 1,373.0 pence per share.
- Treasury Holdings (Settled): 509,064,248 shares (9.14% of total issued share capital).
- Treasury Holdings (Including Unsettled): 510,989,248 shares (10.09% of current total voting rights).
- Shares in Issue (Excluding Treasury): 5,062,665,054 shares.
Material Changes
The primary material change is the reduction of outstanding shares through the purchase of 800,000 shares for Treasury. Consequently, the percentage of total voting rights held in Treasury increased to 10.09% when including unsettled shares.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on operational outlook, or discussion of risks and contingencies. It is a compliance announcement confirming conformity with the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of shares in issue (5,062,665,054) for calculating disclosure thresholds under FSA rules.
- Confirm the current Treasury share count and its impact on total voting rights (10.09% including unsettled).
- Note that the transaction price ranged between 1,373.0 and 1,398.5 pence per share.
- Understand that this filing does not constitute an offer to purchase or subscribe for securities.